Pharmacovigilance in the era of real-world data
A medicine’s licence is the beginning of its safety story, not the end. Modern pharmacovigilance is one of the fastest-evolving disciplines in the life sciences.
No clinical trial can fully characterise a medicine’s safety. Pre-approval studies involve limited numbers of patients, follow them for limited periods, and often exclude the elderly, the pregnant, the multi-morbid and the very young — precisely the people who will take the medicine once it is marketed. Rare adverse reactions, delayed effects and interactions in complex patients can only be detected once a product is used at scale in real populations. That is the permanent case for pharmacovigilance.
From thalidomide to modern systems
Modern drug-safety science was born from failure: the thalidomide disaster of the late 1950s and early 1960s, in which a sedative marketed to pregnant women caused severe congenital malformations in thousands of children, led directly to the systematic adverse-event reporting and stronger licensing requirements that define regulation today.[1] Six decades later, pharmacovigilance is a globally harmonised discipline: national and regional systems collect spontaneous reports at scale, and international standards — from the ICH guidelines to the EU’s Good Pharmacovigilance Practices modules — define how marketing-authorisation holders must detect, assess and act on safety signals across a product’s entire lifecycle.
What is changing now
- Signal detection at scale. Large spontaneous-reporting databases are mined with disproportionality statistics and, increasingly, machine-learning methods across the pharmacovigilance lifecycle[2] — demanding analysts who understand both the pharmacology and the limitations of the data.
- Real-world evidence. Electronic health records, claims data and registries now complement spontaneous reports — the US FDA finalised dedicated guidance on using EHR and claims data for regulatory decision-making in 2024[3] — supporting faster hypothesis testing and formal post-authorisation safety studies.
- Lifecycle obligations. Risk-management plans, periodic safety-update reports and post-market surveillance duties for medical devices have turned safety from a reactive function into a continuous, planned discipline.
The career signal: pharmacovigilance, post-market surveillance and real-world-evidence roles consistently appear among the most in-demand functions in pharmaceutical and medical-device organisations — and they increasingly require demonstrable, assessed competence rather than on-the-job familiarity alone.
Professional recognition in drug safety
The EUSTM Academy addresses this space with three complementary credentials: the Professional Certification in Drug Safety & Pharmacovigilance (PCDSPV) for the core discipline, the Professional Certification in Real-World Evidence (PCRWE) for observational data science, and the Professional Certification in Post-Market Surveillance (PCPMS) for device vigilance.
References
- Javid M, Nandave M, Kumar A. History of Pharmacovigilance. In: Pharmacovigilance Essentials. Springer, Singapore (2024). doi: 10.1007/978-981-99-8949-2_2
- An industry perspective on the use of machine learning in drug and vaccine safety. Frontiers in Drug Safety and Regulation (2023). doi: 10.3389/fdsfr.2023.1110498
- US Food and Drug Administration. Real-World Data: Assessing Electronic Health Records and Medical Claims Data To Support Regulatory Decision-Making for Drug and Biological Products — final guidance (2024). fda.gov